tremelimumab   Click here for help

GtoPdb Ligand ID: 8462

Synonyms: CP-675 | CP-675,206 | CP-675206 | Imjudo® | ticilimumab | tremelimumab-actl
Approved drug Immunopharmacology Ligand
tremelimumab is an approved drug (FDA (2022), EMA (2023))
Compound class: Antibody
Comment: Tremelimumab is a fully human investigational monoclonal antibody targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA4, CD152). Tremelimumab was designed as an antineoplastic agent. A BLAST sequence alignment matches tremelimumab to patent US 6682736, and identifies antibody clone 11.2.1 [2].
Click here for help
Classification Click here for help
Compound class Antibody
Ligand families/groups Immune checkpoint modulators
Approved drug? Yes (FDA (2022), EMA (2023))
International Nonproprietary Names Click here for help
INN number INN
8716 tremelimumab
Synonyms Click here for help
CP-675 | CP-675,206 | CP-675206 | Imjudo® | ticilimumab | tremelimumab-actl
Database Links Click here for help
Specialist databases
IMGT/mAb-DB 248
Other databases
GtoPdb PubChem SID 252166672
Search PubMed clinical trials tremelimumab
Search PubMed titles tremelimumab
Search PubMed titles/abstracts tremelimumab
Wikipedia Tremelimumab